CA2284820A1 - Nouvelle utilisation de l'antithrombine iii - Google Patents
Nouvelle utilisation de l'antithrombine iii Download PDFInfo
- Publication number
- CA2284820A1 CA2284820A1 CA002284820A CA2284820A CA2284820A1 CA 2284820 A1 CA2284820 A1 CA 2284820A1 CA 002284820 A CA002284820 A CA 002284820A CA 2284820 A CA2284820 A CA 2284820A CA 2284820 A1 CA2284820 A1 CA 2284820A1
- Authority
- CA
- Canada
- Prior art keywords
- iii
- preparation
- heparin
- use according
- heparins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004411 Antithrombin III Human genes 0.000 title claims 2
- 108090000935 Antithrombin III Proteins 0.000 title claims 2
- 229960005348 antithrombin iii Drugs 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 11
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 11
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 11
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 5
- 230000000740 bleeding effect Effects 0.000 claims abstract description 3
- 229920000669 heparin Polymers 0.000 claims description 67
- 229960002897 heparin Drugs 0.000 claims description 64
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 55
- 238000002360 preparation method Methods 0.000 claims description 33
- 208000002193 Pain Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 230000036407 pain Effects 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 7
- 229920001499 Heparinoid Polymers 0.000 claims description 6
- 239000002554 heparinoid Substances 0.000 claims description 6
- 206010018852 Haematoma Diseases 0.000 claims description 5
- 229940025770 heparinoids Drugs 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000007395 thrombosis prophylaxis Methods 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- GVOIQSXBMLNCLC-UHFFFAOYSA-N OOOS Chemical compound OOOS GVOIQSXBMLNCLC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001577 copolymer Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940019334 heparin group antithrombotic drug Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- WTEALAUFHBQTEJ-UHFFFAOYSA-N ristocetin sulfate Chemical compound OS(O)(=O)=O.C=1C2=CC=C(O)C=1C1=C(OC3C(C(O)C(O)C(CO)O3)O)C=C(O)C=C1C(C(=O)OC)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(C=3C=C(C(=C(O)C=3)C)OC=3C(O)=CC=C(C=3)C(N)C(=O)N3)NC(=O)C3C(O)C(C=C3)=CC=C3OC(C=3OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(C)O5)O)O4)O)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(N)C(O)C(C)O1 WTEALAUFHBQTEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT51797A AT405905B (de) | 1997-03-25 | 1997-03-25 | Neue verwendung von antithrombin iii |
ATA517/97 | 1997-03-25 | ||
PCT/AT1998/000078 WO1998042371A1 (fr) | 1997-03-25 | 1998-03-24 | Nouvelle utilisation d'antithrombine iii |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2284820A1 true CA2284820A1 (fr) | 1998-10-01 |
Family
ID=3492718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002284820A Abandoned CA2284820A1 (fr) | 1997-03-25 | 1998-03-24 | Nouvelle utilisation de l'antithrombine iii |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0971732A1 (fr) |
AT (1) | AT405905B (fr) |
AU (1) | AU6385298A (fr) |
CA (1) | CA2284820A1 (fr) |
WO (1) | WO1998042371A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5810091B2 (ja) * | 2009-11-24 | 2015-11-11 | グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. | 凍結乾燥方法、組成物、及びキット |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3170001D1 (en) * | 1980-09-30 | 1985-05-23 | Bayer Ag | Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex |
US4689323A (en) * | 1983-09-26 | 1987-08-25 | Miles Laboratories, Inc. | Covalently bound heparin--antithrombin-III complex |
JP3494667B2 (ja) * | 1992-10-02 | 2004-02-09 | アベンティス ファーマ株式会社 | アンチトロンビンiii製剤 |
JP3820607B2 (ja) * | 1995-11-10 | 2006-09-13 | 三菱ウェルファーマ株式会社 | アンチトロンビン−iiiの液状製剤およびその保存安定化方法 |
US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターiiの医薬用途 |
-
1997
- 1997-03-25 AT AT51797A patent/AT405905B/de not_active IP Right Cessation
-
1998
- 1998-03-24 EP EP98909214A patent/EP0971732A1/fr not_active Withdrawn
- 1998-03-24 AU AU63852/98A patent/AU6385298A/en not_active Abandoned
- 1998-03-24 CA CA002284820A patent/CA2284820A1/fr not_active Abandoned
- 1998-03-24 WO PCT/AT1998/000078 patent/WO1998042371A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AT405905B (de) | 1999-12-27 |
AU6385298A (en) | 1998-10-20 |
ATA51797A (de) | 1999-05-15 |
EP0971732A1 (fr) | 2000-01-19 |
WO1998042371A1 (fr) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5691312A (en) | Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides | |
Mombelli et al. | Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. | |
US20080113960A1 (en) | Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor | |
EP0497756B1 (fr) | Composition antithrombose | |
CN114392228A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
EP1226829A2 (fr) | Préparations liquides stabilisées de la protéase ou de son proenzyme qui activent le facteur VII de la coagulation sanguine | |
AU696954B2 (en) | Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications | |
Mariani et al. | Treatment of congenital factor VII deficiency with a new concentrate | |
Tibballs et al. | The cardiovascular and haematological effects of purified prothrombin activator from the common brown snake (Pseudonaja textilis) and their antagonism with heparin | |
US6174855B1 (en) | Pharmaceutical compositions comprising thrombin inhibitors and their use in the control of wound healing processes | |
EP0625908A1 (fr) | Antidote pour l'hirudine et les inhibiteurs synthetiques de la thrombine | |
KR100416677B1 (ko) | 트롬빈억제제를함유하는주입용저장안정성수용액 | |
US5767106A (en) | Treatment of disease and conditions associated with macrophage infiltration | |
CA2284820A1 (fr) | Nouvelle utilisation de l'antithrombine iii | |
WO1996005845A2 (fr) | Traitement de maladies et de troubles associes a des infiltrations de macrophages, notamment les apoplexies et les infarctus du myocarde | |
US20070275086A1 (en) | Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy | |
WO1992020361A1 (fr) | Nouvelle combinaison de facteur viii et d'un antifibrinolytique | |
JPH07502734A (ja) | 血液損失を減少する方法および組成物 | |
Brill-Edwards et al. | Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: Implications for antithrombotic therapy | |
JPS63503542A (ja) | 新規組成物 | |
Ozen et al. | Low-dose intranasal desmopressin (DDAVP) for uremic bleeding | |
EP0733371B1 (fr) | Agent pour l'application sous-coutanée de la protéine C | |
Peternel et al. | Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models | |
Arnesen et al. | What is the optimal dosage of LMW heparin in the SC treatment of deep venous thrombosis | |
Soulier et al. | In vivo attempt to consume antithrombin III by iv injection of a thrombin-heparin mixture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |